Atlantic Union Bankshares Corp Has $5.76 Million Position in Zoetis Inc. $ZTS

Atlantic Union Bankshares Corp lowered its position in Zoetis Inc. (NYSE:ZTS) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,785 shares of the company’s stock after selling 10,496 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Zoetis were worth $5,761,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates bought a new stake in Zoetis in the fourth quarter valued at approximately $25,000. Lodestone Wealth Management LLC bought a new position in shares of Zoetis in the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis in the 3rd quarter worth $31,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis in the 4th quarter worth $32,000. Finally, Board of the Pension Protection Fund bought a new position in Zoetis during the 4th quarter valued at $38,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZTS. JPMorgan Chase & Co. dropped their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Stifel Nicolaus set a $105.00 price objective on Zoetis in a report on Friday, May 8th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $141.25.

Insider Activity

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $74.32 on Thursday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a fifty-two week low of $74.29 and a fifty-two week high of $172.23. The stock has a 50 day moving average price of $114.33 and a two-hundred day moving average price of $121.77. The company has a market capitalization of $31.16 billion, a P/E ratio of 12.33, a PEG ratio of 1.26 and a beta of 0.87.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the previous year, the firm posted $1.48 EPS. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.